Japan · Delayed Price · Currency is JPY J-Pharma Statistics
Total Valuation
J-Pharma has a market cap or net worth of JPY 7.46 billion. The enterprise value is 3.01 billion.
| Market Cap | 7.46B |
| Enterprise Value | 3.01B |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
J-Pharma has 17.98 million shares outstanding.
| Current Share Class | 17.98M |
| Shares Outstanding | 17.98M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.65% |
| Owned by Institutions (%) | 24.70% |
| Float | 10.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.22 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.34 |
Financial Position
The company has a current ratio of 12.57
| Current Ratio | 12.57 |
| Quick Ratio | 11.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -73.01% and return on invested capital (ROIC) is -68.64%.
| Return on Equity (ROE) | -73.01% |
| Return on Assets (ROA) | -60.88% |
| Return on Invested Capital (ROIC) | -68.64% |
| Return on Capital Employed (ROCE) | -84.64% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, J-Pharma has paid 1.12 million in taxes.
| Income Tax | 1.12M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 22.56 |
| Average Volume (20 Days) | 39,310 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.71B |
| Pretax Income | -2.47B |
| Net Income | -2.47B |
| EBITDA | -3.71B |
| EBIT | -3.71B |
| Earnings Per Share (EPS) | -195.08 |
Balance Sheet
The company has 4.45 billion in cash and n/a in debt, with a net cash position of 4.45 billion or 247.60 per share.
| Cash & Cash Equivalents | 4.45B |
| Total Debt | n/a |
| Net Cash | 4.45B |
| Net Cash Per Share | 247.60 |
| Equity (Book Value) | 4.38B |
| Book Value Per Share | 243.47 |
| Working Capital | 4.38B |
Cash Flow
In the last 12 months, operating cash flow was -2.25 billion and capital expenditures -4.02 million, giving a free cash flow of -2.25 billion.
| Operating Cash Flow | -2.25B |
| Capital Expenditures | -4.02M |
| Depreciation & Amortization | 1.22M |
| Net Borrowing | n/a |
| Free Cash Flow | -2.25B |
| FCF Per Share | -125.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
J-Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -33.05% |
| FCF Yield | -30.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |